Drug treatment of hypertension in the elderly: The role of a-adrenoceptor blockade

British Journal of Urology

Volumn 81, Issue SUPPL. 1, 1998, Pages 21-25

  Man Veld, A J ^a,b   Van Der Camme, T J M ^a   Van Loon, K ^a  

^a Renal Diseases and Geriatric Medicine   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; METHYLDOPA; NIFEDIPINE; NITRENDIPINE; PRAZOSIN; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ADULT; AGED; ASTHENIA; CARDIOVASCULAR DISEASE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FALLING; GERIATRICS; GOUT; HEADACHE; HUMAN; HYPERTENSION; IMPOTENCE; ISCHEMIC HEART DISEASE; LETHARGY; MORBIDITY; MORTALITY; MUSCLE CRAMP; NAUSEA; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SKIN DISEASE; STROKE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ACCIDENTAL FALLS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION;

EID: 0031874018     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.0810s1021.x     Document Type: Article

References (39)

1. Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-83
2. National High Blood Pressure Education Program Working Group. Report on primary prevention of hypertension. Arch Intern Med 1993; 153: 186-206
3. National High Blood Pressure Education Program Working Group. Report on hypertension in the elderly. Hypertension 1994; 23: 275-85
4. Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981; ii: 539-43
5. Report of the Management Committee of the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Med J Aust 1981; 2: 398-402
6. Amery A, Birkenhäger W, Brixko P et al. Mortality and morbidity results from the European Working Group Party on High Blood Pressure in the Elderly Trial, lancet 1985; i: 1349-54
7. Coope J. Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986; 293: 1145-51
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64
9. Dahlöf B. Lindholm LH. Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Older Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5
10. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Er Med J 1992; 304: 405-12
11. Lever AF. Ramsay LE. Treatment of hypertension in the elderly. J Hypertens 1995: 13: 571-9
12. Beard K, Bulpitt C. Mascie-Taylor H, O'Malley K, Sever P. Webb S. Management of elderly patients with sustained hypertension. Br MedJ 1992; 304: 412-6
13. 3 Anonymous. New trials in older hypertensives [editorial J. Lancet 1991; 338: 1299-300
14. Staessen J. Fagard R. Amery A. Isolated systolic hypertension in the elderly: implications of SHEP for clinical practice and for the ongoing trials. J Hum Hypertens 1991: 5: 469-74
15. 5 Sever P. Beevers G. Bulpitt C ft al. Management guidelines in essential hypertension: report of the second working group of the British Hypertension Society. Br Med J 1993: 306: 983-7
16. Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18
17. Medical Research Council Working Group. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Br Med J 1988; 296: 1565-70
18. Collins R. Peto R. MacMahon S et al. Blood pressure, stroke, and coronary heart disease, part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38
19. Cruickshank JM. Thorp JM, Zacharias FJ. Benefits and potential harm of lowering blood pressure. Lancet 1987; i: 581-4
20. The HOT Study Group. The Hypertension Optimal Treatment (HOT) study: a prospective study of the optimal therapeutic goal and the values of low-dose aspirin in antihypertensive treatment. Blood Pressure 1993: 2: 113-9
21. Staessen J, Dekempeneer L. Fagard R et al. Treatment of isolated systolic hypertension in the elderly. J Cardiovasc Pharmacol 1991; 18 (suppl 1): S34-S40
22. Amery A. Birkenhäger W, Bulpitt CJ et al. Syst-Eur: A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives protocol, and organization. Ageing 1991: 3: 287-302
23. Staessen JA. Fagard R. Thijs L et al. for the Systolic Hypertension in Europe (Syst-Eur) trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64
24. Moser M. Drug treatment of hypertension in the elderly and in diabetics. In van Zwieten PA, Greenbee WJ. eds, Antihypertensive Drugs. Harwood Academic Publishers 1997: 501-28
25. Brogden RN. Heel RC. Speight TM, Avery GS. Prazosin: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 1977; 14: 163-97
26. Stomaszek WF. Kellerman D, Brogden RN, Romankiewicz Prazosin update: A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 1983; 25: 339-84
27. Wilde MI. Fitton A, McTarrish D. Alfusosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs 1993: 45: 410-29
28. Titmarsh S. Monk JP. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in essential hypertension. Drugs 1987: 33: 461-77
29. Wilde MI. Fitton A. Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs Ageing 1993: 3: 258-77
30. Young RA, Brogden RN. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild to moderate hypertension. Drags 1988: 35: 525-41
31. Fulton B. Wagstaff AJ. Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995: 49: 295-320
32. Wilde MI. McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996; 52: 883-98
33. Campbell AJ. Reinken J. Alien BC. Martinez GS. Falls in old age: A study of frequency and related clinical factors. Ageing 1981; 10: 264-70
34. Sattin RW. Falls among older persons: A public health perspective. Ann Rev Public Health 1992: 13: 489-508
35. Tinetti M, Speechley M. Ginter SF. Risk factors for falls among elderly persons living in the community. N Eng J Med 1988; 319: 1701-7
36. Grisso JA. Kelsey JL. Strom BL et al. Risk factors for falls as a cause for hip fracture in women. N Eng J Med 1991; 324: 1326-31
37. Englander F. Hudson TJ. Terregrossa RA. Economic dimensions of slip and fall injuries. J Forensic Sci 1996:41: 733-46
38. Tinetti ME. Speechley M. Prevention of falls among the elderly. N Eng J Med 1989: 320: 1055-9
39. Tinetti ME. Baker DI, McAvay G et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community.